Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer

ClinicalTrials.gov ID: NCT05113251

Public ClinicalTrials.gov record NCT05113251. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 28, 2026, 1:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3 Open-label Trial of Neoadjuvant Trastuzumab Deruxtecan (T-DXd) Monotherapy or T-DXd Followed by THP Compared to ddAC-THP in Participants With High-risk HER2-positive Early-stage Breast Cancer (DESTINY-Breast11)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will look at the efficacy and safety of trastuzumab deruxtecan (T-DXd) in a neoadjuvant setting, in high-risk, HER2-positive early non-metastatic breast cancer.

Study identification

NCT ID: NCT05113251
Recruitment status: Active, not recruiting
Study type: Interventional
Phase: Phase 3
Lead sponsor: AstraZeneca; Industry
Enrollment: 927 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Oct 25, 2021 (Actual)
Primary completion: Mar 12, 2025 (Actual)
Completion: Apr 30, 2027 (Estimated)
Last update posted: Aug 11, 2026

2021 – 2027

United States locations

U.S. sites: 22
U.S. states: 16
U.S. cities: 22

Facility	City	State	ZIP	Site status
Research Site	Springdale	Arkansas	72762	—
Research Site	Beverly Hills	California	90211	—
Research Site	Glendale	California	91204	—
Research Site	Los Alamitos	California	90720	—
Research Site	Orange	California	92868	—
Research Site	New Haven	Connecticut	06510	—
Research Site	Fort Wayne	Indiana	46804	—
Research Site	Lexington	Kentucky	40503	—
Research Site	Louisville	Kentucky	40202	—
Research Site	Shreveport	Louisiana	71101	—
Research Site	Minneapolis	Minnesota	55407	—
Research Site	Las Vegas	Nevada	89102	—
Research Site	East Brunswick	New Jersey	08816	—
Research Site	Summit	New Jersey	07901	—
Research Site	Commack	New York	11725	—
Research Site	Durham	North Carolina	27710	—
Research Site	Greenville	South Carolina	29607	—
Research Site	Germantown	Tennessee	38138	—
Research Site	Nashville	Tennessee	37203	—
Research Site	Fort Worth	Texas	76104	—
Research Site	Ogden	Utah	84405	—
Research Site	Tacoma	Washington	98405	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 123 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05113251, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 11, 2026 · Synced Oct 28, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT05113251 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →